Hypothesis

Age‑related NAD+ loss does not merely reflect metabolic wear; it actively licenses the microglial complement cascade that drives maladaptive synaptic pruning. When NAD+ falls, SIRT1 deacetylase activity drops, leading to hyperacetylation (and thus increased transcriptional activity) of NF‑κB p65 in microglia. This shifts microglia toward a proinflammatory state that upregulates C1q, C3, and C4, tagging synapses for elimination. Restoring NAD+ or boosting SIRT1 should blunt complement‑mediated synapse loss even if upstream pathologies (e.g., amyloid‑β) remain unchanged.

Mechanistic Rationale

• NAD+ fuels SIRT1: SIRT1 requires NAD+ as a co‑factor to remove acetyl groups from histones and transcription factors. In microglia, SIRT1 restrains NF‑κB by deacetylating p65 at Lys310, reducing its DNA‑binding affinity and transcriptional potency.[5]
• NAD+ decline → SIRT1 inhibition → NF‑κB hyperacetylation: Lower NAD+ diminishes SIRT1 activity, causing p65 to stay acetylated, which enhances its affinity for κB sites on complement gene promoters and stabilizes its interaction with co‑activators like CBP/p300.
• Microglia as the dominant CNS source of complement: Aging microglia, not astrocytes, produce the bulk of C1q and C3 that opsonize synapses.[2] Thus, a microglial‑specific metabolic switch can directly amplify the complement‑synapse pruning axis.
• Parallel to developmental pruning: During development, microglial complement expression is tightly timed and then silenced. The hypothesis posits that age‑related NAD+ loss mimics a developmental "re‑opening" signal by lifting SIRT1‑mediated repression.

Testable Predictions

1. Microglia‑specific NAD+ depletion elevates complement

   • Use Cx3cr1‑CreER; Nampt^fl/fl mice to delete Nampt (rate‑limiting NAD+ salvage enzyme) in microglia of young adult mice.
   • Measure C1q, C3, and C4 mRNA/protein in isolated microglia (qPCR, Western) and synaptic C3b/iC3b deposition (immunohistochemistry).
   • Prediction: NAD+‑deficient microglia show ≥2‑fold increase in complement components and heightened synaptic tagging versus controls.

2. SIRT1 loss phenocopies NAD+ depletion

   • Cross Cx3cr1‑CreER; SIRT1^fl/fl mice and assess complement readouts as above.
   • Prediction: SIRT1 knockout microglia recapitulate the complement increase seen with Nampt loss.

3. Pharmacological NAD+ restoration suppresses complement

   • Treat aged wild‑type mice or Nampt‑deficient microglia cultures with NR (nicotinamide riboside) or NMN for 4 weeks.
   • Assess microglial complement expression and synaptic density (synaptophysin/PSD‑95 staining).
   • Prediction: NAD+ repletion reduces complement levels to youthful levels and preserves synapses without altering amyloid‑β load.

4. SIRT1 activation bypasses NAD+ requirement

   • Apply the SIRT1 activator SRT2104 to Nampt‑deficient microglia or aged mice.
   • Prediction: SIRT1 activation normalizes NF‑κB acetylation (measured by acetyl‑p65 Lys310 Western) and lowers complement despite low NAD+.

5. NF‑κB acetylation is the critical node

   • Introduce a non‑acetylatable p65 mutant (K310R) via AAV into microglia of Nampt‑deficient mice.
   • Prediction: Blocking p65 acetylation prevents complement up‑regulation and synaptic loss, even when NAD+ is depleted.

Falsifiability

If any of the following occur, the hypothesis is weakened or refuted:

• Microglial Nampt deletion fails to raise complement or synaptic C3b despite confirmed NAD+ drop.
• SIRT1 loss does not increase NF‑κB acetylation or complement expression.
• NAD+ supplementation does not diminish microglial complement or rescue synapses in aged mice.
• SIRT1 activation fails to lower complement when NAD+ remains low.
• Blocking p65 acetylation does not prevent complement elevation in NAD+‑deficient microglia.

Such outcomes would suggest that NAD+ influences complement through alternative pathways (e.g., metabolic signaling, inflammasome activation) or that the two processes are largely independent hallmarks of aging.

Therapeutic Implication

Demonstrating a causal NAD+→SIRT1→NF‑κB→complement axis would justify targeting NAD+ metabolism or SIRT1 not as broad "anti‑aging" supplements but as precise modifiers of microglial immune programming to halt synapse loss in Alzheimer’s, tauopathies, and ALS/FTD, irrespective of the primary proteinopathy.